NASDAQ:SYBX

Synlogic (SYBX) Stock Price, News & Analysis

$1.84
-0.03 (-1.60%)
(As of 04/22/2024 ET)
Today's Range
$1.79
$1.94
50-Day Range
$1.73
$1.97
52-Week Range
$1.55
$10.20
Volume
21,725 shs
Average Volume
117,507 shs
Market Capitalization
$21.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00

Synlogic MarketRank™ Stock Analysis

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
3,432.6% Upside
$65.00 Price Target
Short Interest
Healthy
0.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Synlogic in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$969 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.09) to ($3.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

569th out of 909 stocks

Pharmaceutical Preparations Industry

255th out of 422 stocks

SYBX stock logo

About Synlogic Stock (NASDAQ:SYBX)

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

SYBX Stock Price History

SYBX Stock News Headlines

Synlogic, Inc. (SYBX)
[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
Synlogic Adopts Limited Duration Stockholders Rights Plan
Synlogic Adopts Limited Duration Stockholders Rights Plan
[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
Synlogic just downgraded at Chardan, here's why
Why Is Synlogic (SYBX) Stock Down 55% Today?
Synlogic Inc (MIN.MU)
See More Headlines
Receive SYBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SYBX
Employees
6
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$65.00
High Stock Price Target
$90.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+3,432.6%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-57,280,000.00
Net Margins
-1,699.23%
Pretax Margin
-1,698.84%

Debt

Sales & Book Value

Annual Sales
$3.37 million
Book Value
$4.64 per share

Miscellaneous

Free Float
10,714,000
Market Cap
$21.44 million
Optionable
Optionable
Beta
1.09

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Antoine Awad (Age 43)
    Principal Executive Officer & COO
    Comp: $566.55k
  • Dr. Timothy K. Lu M.D. (Age 43)
    Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Dr. James J. Collins Ph.D. (Age 57)
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Mary Beth Dooley (Age 43)
    Head of Finance and Principal Financial Officer & Principal Accounting Officer
  • Mr. Brendan St. Amant
    General Counsel & Corporate Secretary
  • Mr. Ajay Munshi
    Vice President of Corporate Development
  • Mr. Adam J. Thomas
    Chief People Officer
  • Dr. Caroline B. Kurtz Ph.D.
    Chief Development Officer
  • Ms. Molly Harper (Age 47)
    Chief Business Officer
  • Dr. Neal Sondheimer M.D.
    Ph.D., VP & Head of Clinical

SYBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Synlogic stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SYBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYBX, but not buy additional shares or sell existing shares.
View SYBX analyst ratings
or view top-rated stocks.

What is Synlogic's stock price target for 2024?

5 Wall Street research analysts have issued twelve-month target prices for Synlogic's shares. Their SYBX share price targets range from $30.00 to $90.00. On average, they expect the company's share price to reach $65.00 in the next twelve months. This suggests a possible upside of 3,432.6% from the stock's current price.
View analysts price targets for SYBX
or view top-rated stocks among Wall Street analysts.

How have SYBX shares performed in 2024?

Synlogic's stock was trading at $3.85 at the beginning of the year. Since then, SYBX shares have decreased by 52.2% and is now trading at $1.84.
View the best growth stocks for 2024 here
.

Are investors shorting Synlogic?

Synlogic saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 38,600 shares, an increase of 70.8% from the March 15th total of 22,600 shares. Based on an average trading volume of 130,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.6% of the shares of the company are sold short.
View Synlogic's Short Interest
.

When is Synlogic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SYBX earnings forecast
.

How were Synlogic's earnings last quarter?

Synlogic, Inc. (NASDAQ:SYBX) released its quarterly earnings results on Tuesday, March, 19th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by $0.60. The biotechnology company had revenue of $2.77 million for the quarter, compared to analysts' expectations of $2.71 million. Synlogic had a negative net margin of 1,699.23% and a negative trailing twelve-month return on equity of 109.34%.

When did Synlogic's stock split?

Shares of Synlogic reverse split on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Synlogic own?
How do I buy shares of Synlogic?

Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SYBX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners